Longitudinal determination of serum placental protein 13 during development of preeclampsia

Fetal Diagn Ther. 2008;24(3):230-6. doi: 10.1159/000151344. Epub 2008 Aug 28.


Objective: To determine maternal serum placental protein 13 (PP13) in normal pregnancy and preeclampsia.

Methods: A prospective, longitudinal study with 41 normal pregnant women, 18 cases with preterm delivery or cervix insufficiency and 4 with developing late-onset preeclampsia. Six hundred and sixty-six maternal blood samples were obtained every 2-4 weeks starting at 5-8 weeks gestation (10-12 samples/patient) and tested for serum PP13 by ELISA.

Results: In normal pregnant women delivering at term, median maternal serum PP13 levels were growing from 166 to 202 pg/ml and 382 pg/ml in the first, second and third trimester, respectively. Preeclamptic women had significantly reduced PP13 levels in the first trimester (multiples of median of 0.14 at 7-8 weeks; p = 0.005 compared to normal). PP13 in the third trimester was significantly higher compared to normal at 35-36 weeks with PP13 multiples of median of 1.79.

Conclusion: This preliminary study indicates that low levels of PP13 in early pregnancy identify at-risk pregnancies, whereas high levels precede the syndrome in late pregnancy and suggest syncytiotrophoblast necrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Biomarkers / blood
  • Female
  • Galectins / blood*
  • Humans
  • Immunohistochemistry
  • Longitudinal Studies
  • Middle Aged
  • Placenta / metabolism
  • Pre-Eclampsia / blood
  • Pregnancy
  • Pregnancy Proteins / blood*
  • Pregnancy Trimester, First / blood
  • Pregnancy Trimester, Second / blood
  • Pregnancy Trimester, Third / blood
  • Prospective Studies


  • Biomarkers
  • Galectins
  • LGALS13 protein, human
  • Pregnancy Proteins